Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

Annelies Wilder-Smith, Joachim Hombach, Neil Ferguson, Michael Selgelid, Kate O'Brien, Kirsten Vannice, Alan Barrett, Elizabeth Ferdinand, Stefan Flasche, Maria Guzman, Hillegonde Maria Novaes, Lee Ching Ng, Peter G. Smith, Piyanit Tharmaphornpilas, In Kyu Yoon, Alejandro Cravioto, Jeremy Farrar, Terry M. Nolan

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.

Original languageEnglish (US)
Pages (from-to)e31-e38
JournalThe Lancet Infectious Diseases
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Dengue Vaccines
Immunization
Vaccination
Vaccines
Dengue
Seroepidemiologic Studies
Immunization Schedule
Severe Dengue
Needs Assessment
Routine Diagnostic Tests
Population
Clinical Trials
CYD-TDV vaccine
Research

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Wilder-Smith, A., Hombach, J., Ferguson, N., Selgelid, M., O'Brien, K., Vannice, K., ... Nolan, T. M. (2019). Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. The Lancet Infectious Diseases, 19(1), e31-e38. https://doi.org/10.1016/S1473-3099(18)30494-8

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. / Wilder-Smith, Annelies; Hombach, Joachim; Ferguson, Neil; Selgelid, Michael; O'Brien, Kate; Vannice, Kirsten; Barrett, Alan; Ferdinand, Elizabeth; Flasche, Stefan; Guzman, Maria; Novaes, Hillegonde Maria; Ng, Lee Ching; Smith, Peter G.; Tharmaphornpilas, Piyanit; Yoon, In Kyu; Cravioto, Alejandro; Farrar, Jeremy; Nolan, Terry M.

In: The Lancet Infectious Diseases, Vol. 19, No. 1, 01.01.2019, p. e31-e38.

Research output: Contribution to journalReview article

Wilder-Smith, A, Hombach, J, Ferguson, N, Selgelid, M, O'Brien, K, Vannice, K, Barrett, A, Ferdinand, E, Flasche, S, Guzman, M, Novaes, HM, Ng, LC, Smith, PG, Tharmaphornpilas, P, Yoon, IK, Cravioto, A, Farrar, J & Nolan, TM 2019, 'Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine' The Lancet Infectious Diseases, vol. 19, no. 1, pp. e31-e38. https://doi.org/10.1016/S1473-3099(18)30494-8
Wilder-Smith, Annelies ; Hombach, Joachim ; Ferguson, Neil ; Selgelid, Michael ; O'Brien, Kate ; Vannice, Kirsten ; Barrett, Alan ; Ferdinand, Elizabeth ; Flasche, Stefan ; Guzman, Maria ; Novaes, Hillegonde Maria ; Ng, Lee Ching ; Smith, Peter G. ; Tharmaphornpilas, Piyanit ; Yoon, In Kyu ; Cravioto, Alejandro ; Farrar, Jeremy ; Nolan, Terry M. / Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. In: The Lancet Infectious Diseases. 2019 ; Vol. 19, No. 1. pp. e31-e38.
@article{4fdb5024f8d84e7590fe2bf0e31deacc,
title = "Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine",
abstract = "The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80{\%} or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.",
author = "Annelies Wilder-Smith and Joachim Hombach and Neil Ferguson and Michael Selgelid and Kate O'Brien and Kirsten Vannice and Alan Barrett and Elizabeth Ferdinand and Stefan Flasche and Maria Guzman and Novaes, {Hillegonde Maria} and Ng, {Lee Ching} and Smith, {Peter G.} and Piyanit Tharmaphornpilas and Yoon, {In Kyu} and Alejandro Cravioto and Jeremy Farrar and Nolan, {Terry M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/S1473-3099(18)30494-8",
language = "English (US)",
volume = "19",
pages = "e31--e38",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

AU - Wilder-Smith, Annelies

AU - Hombach, Joachim

AU - Ferguson, Neil

AU - Selgelid, Michael

AU - O'Brien, Kate

AU - Vannice, Kirsten

AU - Barrett, Alan

AU - Ferdinand, Elizabeth

AU - Flasche, Stefan

AU - Guzman, Maria

AU - Novaes, Hillegonde Maria

AU - Ng, Lee Ching

AU - Smith, Peter G.

AU - Tharmaphornpilas, Piyanit

AU - Yoon, In Kyu

AU - Cravioto, Alejandro

AU - Farrar, Jeremy

AU - Nolan, Terry M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.

AB - The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.

UR - http://www.scopus.com/inward/record.url?scp=85059232654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059232654&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(18)30494-8

DO - 10.1016/S1473-3099(18)30494-8

M3 - Review article

VL - 19

SP - e31-e38

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 1

ER -